Clinical Research, TRG GEN+, Beirut, Lebanon
Research Article
Variable vs. Fixed Dosing of Monoclonal Antibodies in Oncology
Author(s): Nikolaos Tzenios*, Mary E. Tazanios and Mohamed Chahine
Oncological patients need the proper doses of medications to facilitate their recovery. The two basic approaches used in dosing Monoclonal Antibodies (mAbs) are fixed-dose combination and variable dosing. In Fixed-Dose Combination Drugs (FDCs), two or more active components are combined in a single formulation at a predetermined dose. Variable dosage, which has long been the industry standard, is the polar opposite of this approach. The body changes over time; the Body Surface Area (BSA) in square meters is often used as a Measure (m2). This study uses a systematic review. Most mAbs used in oncology are predominantly given as cytotoxic anticancer drugs using body-size-based (variable) regimens. Despite the benefits of fixed-dose, variable dosing has become the industry standard, despite being criticized for ineffectiveness. While variable dosing has some advantages, the prevalent view.. View More»
DOI:
10.4172/2572 5130.22.7(10).1000218
